Recombinant Factor VIIa + Biological/Vaccine: Placebo
Phase 3Recruiting 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Intracerebral Hemorrhage
Conditions
Intracerebral Hemorrhage
Trial Timeline
May 6, 2025 → Jun 1, 2029
NCT ID
NCT07227246About Recombinant Factor VIIa + Biological/Vaccine: Placebo
Recombinant Factor VIIa + Biological/Vaccine: Placebo is a phase 3 stage product being developed by Novo Nordisk for Intracerebral Hemorrhage. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07227246. Target conditions include Intracerebral Hemorrhage.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07227246 | Phase 3 | Recruiting |
Competing Products
6 competing products in Intracerebral Hemorrhage
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Edaravone Dexborneol + Placebo | Sun Pharmaceutical | Phase 2 | 52 |
| NXY-059 | AstraZeneca | Phase 2 | 52 |
| Recombinant Activated Factor VII (rFVIIa) + Placebo | Novo Nordisk | Phase 3 | 76 |
| PF-05230907 | Pfizer | Phase 1 | 32 |
| CN-105 | Tiantan Bio | Phase 2 | 49 |
| Albumin + Placebo | Baxter | Phase 2 | 49 |